Compare CNDT & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNDT | KRRO |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | 51000 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.2M | 187.9M |
| IPO Year | 2016 | 2019 |
| Metric | CNDT | KRRO |
|---|---|---|
| Price | $1.61 | $13.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | ★ 935.5K | 67.6K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,042,000,000.00 | $6,392,000.00 |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $1.15 | $5.20 |
| 52 Week High | $2.98 | $55.89 |
| Indicator | CNDT | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 55.16 |
| Support Level | $1.35 | $12.63 |
| Resistance Level | $1.62 | $14.42 |
| Average True Range (ATR) | 0.11 | 0.84 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 28.57 | 74.25 |
Conduent Inc acts as a provider of business process services with expertise in transaction-intensive processing, analytics, and automation. The company provides industry-focused service offerings in growth markets such as Healthcare and Transportation, as well as provides multi-industry services such as transaction processing, customer care, and payment services. It operates through three segments, namely Commercial Industries, which is the key revenue-driving segment, Government Services, and Transportation. The group operates its business in the United States, Europe, and Other areas, of which the majority of revenue is generated in the United States.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.